Translational research of "A multicenter Phase II basket study of Brigatinib in patients with ALK fusion gene-positive advanced/recurrent solid tumors"
Not Applicable
Recruiting
- Conditions
- ALK fusion gene positive advanced/recurrent solid tumors except for non-small cell lung cancer
- Registration Number
- JPRN-UMIN000047903
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To explore biomarkers for therapeutic efficacy and resistance mechanisms of brigatinib therapy in patients with Anaplastic lymphoma kinase (ALK) fusion gene positive solid tumors.
- Secondary Outcome Measures
Name Time Method